Happy 53rd Birthday GIK

Nearly 53 years ago, the use of glucose, insulin and potassium (GIK) infusions were introduced into medical practice to reduce myocardial injury during a heart attack1 and subsequently applied to cardiac surgery. What particular component(s) of GIK, the glucose, insulin and/or potassium, provide myocardial benefits for cardiac surgery continues to be studied and questioned. In this month’s Anesthesiology, Duncan and colleagues determined patients subjected to a hyperinsulinemic, normoglycemic clamp had no outcome benefit when compared to patients undergoing standard insulin treatment for aortic valve replacement2. For the study, Duncan and colleagues used speckle tracking echocardiography (STE) to determine there were no differences in myocardial function between the groups (Figure for more detailed explanation). As shown by the authors, STE provides valuable information including myocardial strain and strain rate. However, to apply this technique for routine clinical practice, a number of challenges need to be addressed. Currently, STE remains an offline “after the fact” modality in most centers. The software is not standardized between machines and the data sampling software used is proprietary. This continues to be an ongoing discussion among industry and echocardiography governing societies3. Further, STE remains vulnerable to high signal noise, such as artifacts secondary to aortic valve calcium deposits. This perhaps explains why some of the images were discarded for interpretation in this study. Eventually, these limitations will be solved by ongoing improvements in machines, better practitioner understanding, and incorporation of STE into intraoperative work-flow to make this technique more useful within the operating room. Speckle tracking echocardiography The hyperinsulinemic normoglycemic clamp, proposed almost 20 years ago4, is reported in clinical studies of cardiac bypass surgery to provide beneficial effects including an improvement of cardiac index5, reduction in inflammatory markers6 and lactate levels7. The HINGE trial, using a GIK infusion and supplemental insulin for patients undergoing aortic valve replacement, also found both biochemical and functional improvement for the GIK treatment arm8. The differences in effect seen for the treatment arm in prior studies compared to the study by Duncan and colleagues may be dependent upon the timing, dose(s), duration of treatment, and biochemical markers assessed. It is also worth considering that localization, post-translational modification and activity of cellular proteins may be important to evaluate rather than total protein levels, since protein turnover is likely limited during the treatment window. Regardless, a number of additional biochemical and functional parameters measured in this study had no significant differences between the two groups. The findings for this study may imply the benefit of insulin to minimize myocardial injury during cardiac bypass is its role in glycemic control. A strong correlation pre-clinically between the level of hyperglycemia and degree of myocardial injury (R2=0.96) has been shown9. Compared to GIK treatments during cardiac surgery decades ago, anesthesiologists now are more vigilant to replete potassium and also maintain tighter glycemic control. In combination with measures considered potentially to reduce myocardial injury during cardiac surgery, such as cardioplegia, remote conditioning, moderate hypothermia, and administering volatile anesthetics and opioids, controlling glucose may provide enough of a beneficial effect without a need to implement hyperinsulinemia. Granted, the GIK debate and GIK iterations, including the hyperinsulinemic clamp, are far from over. Rest assured many additional GIK studies will be celebrated in the future with insulin, cake (dextrose), and presents (new techniques).